This early release article (JCO early release) includes the specific risks and benefits associated with each chemopreventive agent. In women at increased risk of BC age >35 years, tamoxifen (20 mg per day for 5 years) should be discussed as an option to reduce the risk of ER – positive BC. In postmenopausal women, raloxifene (60 mg per day for 5 years) should also be discussed as options for BC risk reduction. These guideline recommendations are for use by medical oncologists, surgical oncologists, gynecologists, primary care physicians, and general practitioners. Click here to read full-text.